10202-92-3

Basic information

• Product Name: 3-methyl-2,4-dinitroaniline
• CAS NO: 10202-92-3
• Molecular Formula: C₇H₇N₃O₄
• Molecular Weight: 197.1482
• Mol File: 10202-92-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 386.5°C at 760 mmHg
• Flash Point: 187.5°C
• Density: 1.497g/cm³
• Vapor Pressure: 3.53E-06mmHg at 25°C
• Refractive Index: 1.656
• CAS DataBase Reference: 3-methyl-2,4-dinitroaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 3-methyl-2,4-dinitroaniline(10202-92-3)
• EPA Substance Registry System: 3-methyl-2,4-dinitroaniline(10202-92-3)

Safety Data

• Hazardous Substances Data: 10202-92-3(Hazardous Substances Data)

Upstream product

• 858843-71-7 2-bromo-4-methyl-3,5-dinitro-aniline 
• 67-68-5 dimethyl sulfoxide 
• 97-02-9 2,4-Dinitroanilin 
• 537-92-8 3-Methylacetanilide 
• 7697-37-2 nitric acid 
• 64-17-5 ethanol 
• 606-20-2 2,6-dinitrotoluene 
• 7803-49-8 hydroxylamine 
• 30366-26-8 2,4-dinitro-3-methylanisole 
• 19406-51-0 4-Amino-2,6-dinitrotoluene 
• 854634-63-2 3-bromo-2,6-dinitro-toluene 

Downstream Products

• 170918-27-1 2.3-Diamino-6-nitrotoluene 
• 79913-56-7 3-chloro-2,6-dinitrotoluene 
• 219312-08-0 4-chloro-2-methyl-3-nitro-aniline 
• 1080522-62-8 methyl 2-(4-(4-(2,4-dichlorophenylsulfonamido)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-5-yloxy)-3-methoxyphenyl)acetate 
• 1080521-20-5 2-(4-(4-(2,4-dichlorophenylsulfonamido)-1H-indazol-5-yloxy)-3-methoxyphenyl)acetic acid 
• 1080522-61-7 methyl 2-(4-(4-amino-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-5-yloxy)-3-methoxyphenyl)acetate 
• 170918-28-2 4-methyl-5-nitrobenzimidazole 
• 183278-00-4 5-methyl-6-nitroquinoxaline 
• 181871-69-2 3-chloro-4-methyl-5-nitro benzoic acid 
• 23291-69-2 2,4-dimethyl-5-nitrobenzimidazole 
• 610-31-1 1,2,4-trinitrobenzene 
• 102312-38-9 2,3,6-trinitro-benzoic acid 
• 56207-39-7 2-methyl-3,6-dinitro-aniline 
• 103753-97-5 2,6-dinitro-3-acetamidotoluene 

Relevant articles and documents

Unexpected nuclear formylation and acetylation of some nitroanilines with dimethyl sulfoxide in the presence of a strong base

When treated with a strong base such as KO'Bu or NaH in dimethyl sulfoxide at room temperature, 2,4-dinitro-, 2-cyano-4-nitro- and 4-cyano-2-nitroanilines were found to undergo regiospecific acylation at the 3-position to afford the corresponding 3-formyl or 3-acetyl derivatives in fair to moderate yields. (C) 2000 Elsevier Science Ltd.

Amination of some 1,3-dinitrobenzenes with liquid ammonia-potassium permanganate

1,3-Dinitrobenzene and some its 2- and 4-substituted derivatives are dehydroaminated in a solution of potassium permanganate in liquid ammonia to give the corresponding mono- or diamino-1,3-dinitro-benzenes. Under the same conditions, 4-fluoro-1,3-dinitrobenzene is converted into 2,4-dinitroaniline via replacement of the fluorine atom, while 2,4-dinitrobenzaldehyde gives rise to 2,4-dinitrobenzamide.

Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists

The present invention concerns novel compounds represented by the Formula:*(formula 02)* wherein: A is R1q(R3R60N)m(Z)(NR2)n; m and q are each 0 or 1, with the proviso that when q is 1, m is 0 and when q is 0, m is 1; Z is C=O or SO 2; n is 1 with the proviso that, when Z is C=O, m is 1; X is -NH-, -CH2-, or -OCH2-; Y is 2-imidazoline, 2-oxazoline, 2-thiazoline, or 4-imidazole; R 1 is H, lower alkyl, or phenyl, with the proviso that, when R1 is H, m is 1; R2, R3, R60 are each independently H, lower alkyl, or phenyl; R4, R5, R6, and R7 are each independently hydrogen, lower alkyl, - CF 3, lower alkoxy, halogen, phenyl, lower alkeny, hydroxyl, lower alkylsulfonamido, or lower cycloalkyl, wherein R2 and R7 optionally may be taken together to form alkylene or alkenylene of 2 to 3 atoms in an unsubstituted or optionally substituted 5-or 6-membered ring, wherein the optional substituents on the ring are halo, lower alkyl, or -CN,with the proviso that, when R7 is hydroxyl or lower alkylsulfonamido, then X is not -NH- when Y is 2-imidazoline. The compounds include pharmaceutically acceptable salts of the above. In the above formula A may be, for example, (R1SO2NR2-), (R3R60NSO2NR2-), or (R3R60NCONR2-). The invention also includes the use of the above compounds, and compositions containing them, as alpha 1A/1L agonists in the treatment of various disease states such as urinary incontinence, nasal congestion, priapism, depression, anxiety, dementia, senility, Alzheimer's, deficiencies in attentiveness and cognition, and eating disorders such as obesity, bulimia, and anorexia.